Citius Pharmaceuticals Company Insiders
CTXR Stock | USD 3.60 0.55 13.25% |
Citius Pharmaceuticals' insiders are aggressively buying. The analysis of insiders' sentiment of trading Citius Pharmaceuticals stock suggests that virtually all insiders are extremely bullish at this time. Citius Pharmaceuticals employs about 22 people. The company is managed by 11 executives with a total tenure of roughly 23 years, averaging almost 2.0 years of service per executive, having 2.0 employees per reported executive.
Myron Holubiak CEO President CEO, Director |
Leonard Mazur Chairman Chairman of the Board, Secretary |
Citius Pharmaceuticals' Insider Buying Vs Selling
100
Selling | Buying |
Latest Trades
2019-09-27 | Myron Z Holubiak | Acquired 558597 @ 0.9 | View | ||
2019-09-25 | Myron Z Holubiak | Acquired 5000 @ 6.02 | View | ||
2019-04-03 | Myron Z Holubiak | Acquired 129450 @ 1.55 | View | ||
2018-08-13 | Myron Z Holubiak | Acquired 784314 @ 1.28 | View | ||
2018-03-28 | Myron Z Holubiak | Acquired 2915 @ 3.09 | View | ||
2017-08-24 | Leonard L Mazur | Acquired 11000 @ 2.68 | View | ||
2017-08-08 | Leonard L Mazur | Acquired 421400 @ 4.13 | View |
Monitoring Citius Pharmaceuticals' insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Citius |
Citius Pharmaceuticals' Workforce Through the Years
Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Citius Pharmaceuticals' future performance. Based on our forecasts, it is anticipated that Citius will maintain a workforce of slightly above 20 employees by December 2024.Citius Pharmaceuticals Management Team Effectiveness
The company has return on total asset (ROA) of (0.2474) % which means that it has lost $0.2474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4149) %, meaning that it created substantial loss on money invested by shareholders. Citius Pharmaceuticals' management efficiency ratios could be used to measure how well Citius Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/29/2024, Return On Tangible Assets is likely to drop to -0.88. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Citius Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 11/29/2024, Total Current Assets is likely to grow to about 41.5 M, while Non Currrent Assets Other are likely to drop slightly above 41.6 K.As of 11/29/2024, Common Stock Shares Outstanding is likely to grow to about 182.7 M, though Net Loss is likely to grow to (28.8 M).
Citius Pharmaceuticals Workforce Comparison
Citius Pharmaceuticals is rated below average in number of employees category among its peers. The total workforce of Health Care industry is currently estimated at about 2,483. Citius Pharmaceuticals maintains roughly 22.0 in number of employees contributing less than 1% to equities under Health Care industry.
Citius Pharmaceuticals Insider Trading History
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Citius Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Citius Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Citius Pharmaceuticals insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Buy/Sell Ratio | # Purchases Trades | # Sales Trades | Total Shares Purchased | Total Shares Sold | |
---|---|---|---|---|---|
2024-09-01 | 1.0 | 4 | 4 | 6,714,866 | 6,714,866 |
2024-06-01 | 1.0 | 2 | 2 | 1,294,498 | 1,294,498 |
2024-03-01 | 0.75 | 3 | 4 | 89,486 | 14,770 |
2017-12-01 | 0.3333 | 1 | 3 | 213,106 | 73,267 |
2017-09-01 | 13.0 | 13 | 1 | 4,088,934 | 1,547,067 |
2016-06-01 | 4.0 | 4 | 1 | 800,000 | 36,212 |
2016-03-01 | 4.3333 | 13 | 3 | 27,871,243 | 0.00 |
Citius Pharmaceuticals Notable Stakeholders
A Citius Pharmaceuticals stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Citius Pharmaceuticals often face trade-offs trying to please all of them. Citius Pharmaceuticals' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Citius Pharmaceuticals' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Myron Holubiak | President CEO, Director | Profile | |
Leonard Mazur | Chairman of the Board, Secretary | Profile | |
Jaime Bartushak | CFO, Principal Financial Officer | Profile | |
Myron MD | Executive Officer | Profile | |
Dhananjay Wadekar | Senior Strategy | Profile | |
Catherine MS | Executive Affairs | Profile | |
Nikolas Burlew | Executive Assurance | Profile | |
Ilanit Allen | Vice Communications | Profile | |
Kelly Creighton | Manufacturing Chemistry | Profile | |
Gary Talarico | Executive Operations | Profile | |
Alan Lader | Senior Assurance | Profile |
About Citius Pharmaceuticals Management Performance
The success or failure of an entity such as Citius Pharmaceuticals often depends on how effective the management is. Citius Pharmaceuticals management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Citius management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Citius management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last Reported | Projected for Next Year | ||
Return On Tangible Assets | (0.84) | (0.88) | |
Return On Capital Employed | (0.43) | (0.41) | |
Return On Assets | (0.28) | (0.30) | |
Return On Equity | (0.41) | (0.39) |
Citius Pharmaceuticals Workforce Analysis
Traditionally, organizations such as Citius Pharmaceuticals use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Citius Pharmaceuticals within its industry.Citius Pharmaceuticals Manpower Efficiency
Return on Citius Pharmaceuticals Manpower
Revenue Per Employee | 0.0 | |
Revenue Per Executive | 0.0 | |
Net Loss Per Employee | 1.5M | |
Net Loss Per Executive | 3M | |
Working Capital Per Employee | 1.3M | |
Working Capital Per Executive | 2.6M |
Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.